The inotropic and vasodilator drug milrinone, in an extended-release oral formulation, appears to improve quality of life and be well tolerated in patients with HFpEF, Australian research shows. A pilot study at the Alfred Hospital randomised 23 patients with symptomatic HFpEF to either the phosphodiesterase type III (PDE3) inhibitor or placebo. Predominantly a safety study, ...
Modest gain from milrinone in HFpEF pilot study
By Mardi Chapman
2 Jul 2020